Archive for August, 2009

Sinovac Biotech Ltd.’s (SVA) H1N1 Vaccine Passes Experts Evaluation Organized by SFDA

(PRNewswire-Asia) — Sinovac Biotech Ltd. (NYSE Amex: SVA), a leading provider of biopharmaceutical products in China, announced today that Sinovac’s H1N1 vaccine has passed the experts evaluation organized by State Food and Drug Administration (SFDA). The vaccine is expected to obtain the production license within this week.

On August 30 and 31, 2009, State Food and Drug Administration (SFDA) organized and held an experts evaluation conference focused on A/H1N1 vaccines to evaluate Sinovac’s H1N1 vaccine, which has recently completed a clinical trial. Top-line results from the trial demonstrated Sinovac’s H1N1 vaccine to have a good safety profile and immunogenicity factors that reach the EU criterion after a single shot. No severe adverse events were reported after inoculation. Based on the results of the evaluation, the experts unanimously agreed that Sinovac’s H1N1 vaccine is applicable to all people from 3 to 60 years old and the vaccination schedule is single shot. The result of the experts evaluation conference will be submitted to SFDA on September 1st, which will be the primary opinion for SFDA to issue the production license.

Sinovac submitted the H1N1 split influenza vaccine without adjuvant for registration approval, which is applicable to all people from 3 to 60 years old. The dosage is 15ug/0.5ml/dose. Only one shot is needed for inoculation.

Mr. Weidong Yin, Chairman, President and CEO of Sinovac commented, “We are very excited to see that our H1N1 vaccine has passed the experts evaluation conference organized by SFDA. The evaluation result will be the important opinion for SFDA to issue the production license. We expect to obtain the production license within one week. With this approval, we can continue to fulfill our mission to provide top-quality vaccines to prevent and control the spreading of H1N1 virus not only in China, but worldwide.”

About Sinovac

Sinovac Biotech Ltd. is a China-based biopharmaceutical company that focuses on the research, development, manufacture and commercialization of vaccines that protect against human infectious diseases. Sinovac’s vaccine products include Healive(R) (hepatitis A), Bilive(R) (combined hepatitis A and B), and Anflu(R) (influenza). Panflu(TM), Sinovac’s pandemic influenza vaccine (H5N1), has already been approved for government stockpiling. Sinovac is developing vaccines for enterovirus 71, universal pandemic influenza, Japanese encephalitis vaccine, and human rabies vaccine. Its wholly owned subsidiary, Tangshan Yian, is conducting field trials for independently developed inactivated animal rabies vaccines.

Safe Harbor Statement

This announcement contains forward-looking statements. These statements are made under the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by words or phrases such as “will,” “expects,” “anticipates,” “future,” “intends,” “plans,” “believes,” “estimates” and similar statements. Among other things, the business outlook and quotations from management in this press release contain forward-looking statements. Statements that are not historical facts, including statements about Sinovac’s beliefs and expectations, are forward-looking statements. Forward-looking statements involve inherent risks and uncertainties. A number of important factors could cause actual results to differ materially from those contained in any forward- looking statement. Sinovac does not undertake any obligation to update any forward-looking statement, except as required under applicable law.

Monday, August 31st, 2009 Uncategorized Comments Off on Sinovac Biotech Ltd.’s (SVA) H1N1 Vaccine Passes Experts Evaluation Organized by SFDA

AuthenTec (AUTH) Expands Software Team and Presence in China

(Business Wire) — AuthenTec (NASDAQ:AUTH), the world’s leading provider of smart fingerprint sensors and solutions, announced today that it is expanding its Shanghai-based operations and has named Dr. Lunji Qiu as Vice President & General Manager of AuthenTec China. Dr. Qiu previously held positions as Vice President of Product Development & General Manager of Atrua Technologies, General Manager of Broadcom China, and held management and engineering positions with Motorola in Singapore. Dr. Qiu will oversee all aspects of AuthenTec China, including business development activities and the expansion of its software, customer support, marketing and sales teams.

“We are extremely pleased to appoint Dr. Qiu to lead our business development efforts and our growing software development team in China,” said Scott Moody, AuthenTec Chairman and CEO. “Dr. Qiu brings a proven track record as a General Manager and has a strong background in fingerprint sensor technology and the mobile handsets market, including experience in embedded systems, software development and customer support. His background and expertise, coupled with our expansion initiatives will help us further pursue the tremendous growth opportunities not only in China but the rest of the world, as well. Customers in the region will see increased emphasis on local support while all our customers will see increased development activities in software including our new TrueSuite™ client application software and smart sensor solutions.”

“I’m excited for this opportunity to lead the AuthenTec China team and continue the momentum and development of AuthenTec’s outstanding technologies to take advantage of the growing opportunities in China and the region,” said Dr. Qiu. “AuthenTec’s total solution is well suited for the leading OEMs and ODMs in China. I also look forward to expanding a strong software development and support infrastructure that will benefit not only customers in the region, but PC and wireless customers around the world.”

AuthenTec’s design center in Shanghai serves as a base of operations for AuthenTec China’s software development, sales and technical support teams. The Company recently added three new players to its 28-member China team, including two senior field applications engineers and a sales account manager. AuthenTec plans to further expand its Shanghai operations through the addition of several software development engineers in the next few months.

China is a key region for growth in AuthenTec’s target markets of notebook PCs, netbooks and smartphones. AuthenTec has the broadest portfolio of silicon fingerprint sensors on the market today, and is expanding its offering to include new smart sensors, software, and client applications that increase touch-based functionality while simplifying the sensor user experience.

Dr. Qiu earned Bachelor’s degree in Engineering from Beijing University of Posts and Telecomm, as well as a Master’s degree and a PhD in Electrical Engineering from the University of Queensland. He currently serves as an adjunct professor at Shanghai International Institute.

About AuthenTec

AuthenTec brings multiple touch-powered features including navigation, personalization, convenience and security to nearly 50 million PCs and peripherals, cell phones and other products. The Company’s newest generation of smart sensors, software and TrueSuite™ client applications give users secure one-touch access to their favorite websites, online social networks and digital identity. AuthenTec has the broadest product and patent portfolio in the industry today, and helps enable the Power of Touch® for millions of people at home, at work or on the move. For more information, visit www.authentec.com or follow us at twitter.com/authentecnews.

Source: Business Wire (August 31, 2009 – 8:00 AM EDT)
Monday, August 31st, 2009 Uncategorized Comments Off on AuthenTec (AUTH) Expands Software Team and Presence in China

Servotronics, Inc. (SVT)

Servotronics, Inc. has established a reputation for its design, development, and manufacture of high quality components, systems and sub-systems for use wherever precise control, reliability and cost containment are required. The company’s products include servocontrol valves, torque motors, actuators, check valves, pressure regulators, metallic seals and many other products which are used in a wide range of applications and industries.

Servotronics is committed to delivering customer satisfaction by meeting and exceeding their product requirements for value, quality, reliability, and on-time deliveries. The company views all challenges as achievement based opportunities for continuous improvement. Viewing itself as a team player, Servotronics’ synergistically combines its employees’ expertise, efforts and support to create the cutting edge of technology and value.

Currently the company trades at a P/E of 6.8 and Market Cap of $18.15 Million. With annual sales of $31.66 Million, the company trades at a Price/Sales Ratio of only 0.45. Over the past five years, annual net income has grown at an average of 60.85% versus the industry average of 12.11%.

In 2010, the company generated net income of $2,128,000 (or $1.01 per share diluted) on revenues of $31,659,000. This compares to net income of $1,903,000 (or $0.98 per share diluted) on revenues of $33,008,000 during 2009, an approximate 11.8% increase in net income.

As of last report, Servotronics had $28.5 Million in assets, $3.2 Million in current liabilities and $3.1 Million in long-term debt. Shareholder equity totals $21.3 Million providing a solid Debt/Equity Ratio of 0.01. The company also boasts a respectable 46.8% Return on Equity, 40.8% Return on Assets and 46.2% Return on Capital.

Key statistics (5/3/11):

Market cap: $18.15 Million
P/E Ratio: 6.8 versus industry average of 13.4
P/S Ratio: 0.45 versus industry average of 0.54
Price/Cash Flow Ratio: 6.20 versus industry average of 10.70

Debt/Equity Ratio: 0.01 versus industry average of 0.43
Current Ratio: 8.9 versus industry average of 0.4
Quick Ratio: 8.9 versus industry average of 0.1
Book Value/Share: $10.75 versus current market price of $9.16

Return on Equity: 46.8% versus industry average of 19.7%
Return on Assets: 40.8% versus industry average of 7.3%
Return on Capital: 46.2% versus industry average of 5.3%
Inventory Turnover: 5.8 versus industry average of 1.9



Saturday, August 22nd, 2009 Uncategorized Comments Off on Servotronics, Inc. (SVT)

Tiens Biotech Group, Inc. (TBV)

Tiens Biotech Group, Inc. conducts most of its business through two of its subsidiaries: Tianjin Tianshi Biological Development Co., Ltd., and Tiens Yihai Co., Ltd. Founded in 1998, Tianjin Tianshi focuses on researching, developing, manufacturing and marketing supplements and personal care products. Tiens Yihai on the other hand focuses on the research and development, production and marketing of nutrition supplements products, home care and personal care products.

Tiens’ herbal products, vitamin and mineral supplements and personal care products are sold in China as well as approximately 90 other countries. The company has significantly increased its revenue and earnings over the years by capitalizing on worldwide consumer demand for nutritional and wellness products. Tiens has positioned itself for further growth through product line enhancements and additional channels of distribution.

As a result of its ongoing R&D efforts, Tiens has developed, manufactured and marketed more than 20 major products and launches 5-to-7 new products each year. Attracting world-class talent to develop its high-quality products, Tiens has built modern research laboratories with superior scientific equipment and provides competitive compensation packages for the research staff. In addition to developing its own products, the company also plans to utilize product acquisitions to expand its product portfolio.

Currently, insiders hold 95.09% of the shares outstanding, which gives them great incentive to protect and build shareholder value. In addition to growing revenues and earnings at such a rapid and consistent rate, the management team has also proven their competence by providing Return on Equity (ROE) of 14.7%, Return on Assets of 11.4%, and Return on Capital of 14.2%. These returns are dramatically higher than the average percentages and speak volumes of the company’s effectiveness.

Key statistics (5/6/10):

Market cap: $155 Million
P/E Ratio: 6.6 versus industry average of 14.2
P/S Ratio: 2.56 versus industry average of 3.65
Price/Cash Flow Ratio: 5.8 versus industry average of 11.2

Debt/Equity Ratio: 0.00 versus industry average of 0.48
Current Ratio: 2.0 versus industry average of 2.7
Quick Ratio: 1.9 versus industry average of 1.9
Book Value/Share: $2.47 versus current market price of $2.17

Return on Equity: 14.7% versus industry average of 12.4%
Return on Assets: 11.4% versus industry average of 4.7%
Return on Capital: 14.2% versus industry average of 6.6%
5-Year average ROE: 20.8% versus industry average of 8.7%

Recent News
Tuesday, August 18th, 2009 Uncategorized Comments Off on Tiens Biotech Group, Inc. (TBV)

Five Star Quality Care, Inc. (FVE)

Five Star Quality Care, Inc. is a national healthcare and senior living services provider focused on building a solid financial base by carefully managing assets, resulting in a better bottom-line and enhanced resident care. With more than 21,000 employees in 230 locations nationwide, the company operates through three major divisions: Five Star Senior Living, Five Star Rehabilitation Services, and Five Star Pharmacy Services.

The Five Star Senior Living division includes more than 200 Independent Living and Assisted Living facilities, Skilled Health Care facilities, and Continuing Care Retirement Communities. Through its Rehabilitation Services division, Five Star operates rehabilitation hospitals and outpatient health rehabilitation clinics. Through its Pharmacy Services division, Five Star operates institutional pharmacies across the country.

There is much opportunity for the company to grow as the aging U.S. population increases demand for independent living properties, assisted living communities, skilled nursing facilities, pharmacies and rehabilitation services. In addition to capitalizing on this industry growth, the company aims to improve profitability of its existing operations by increasing revenues and improving margins. Five Star is also utilizing a proven acquisition strategy for growth and continues to seek additional areas of expansion.

With more than a billion in annual revenues, the company trades at a market cap of $181.8 million, providing a price to sales ratio of only 0.15! Few investors foresee a decline in stock price coming any time soon with less than 4% of the float reportedly shorted. Two analysts currently believe the company is a “Buy”, while one other believes it’s a “Hold”. Currently 46.50% of the shares outstanding are held by institutions while 11.92% are held by insiders.

Most experienced investors would assume at this point that Five Star must have a poor balance sheet and/or revenues are declining, but the company actually has a solid balance sheet with $25.7 million in cash, and revenues have grown at an average of 14.81% the past five years.

Key statistics (12/10/10):

Market cap: $254.70 Million
P/E Ratio: 13.4 versus industry average of 9.3
P/S Ratio: 0.20 versus industry average of 0.93
Price/Cash Flow Ratio: 7.10 versus industry average of 74.60

Debt/Equity Ratio: 0.31 versus industry average of 1.91
Current Ratio: N/A versus industry average of 1.1
Quick Ratio: 1.0 versus industry average of 0.2
Book Value/Share: $4.46 versus current market price of $7.13

Return on Equity: 12.7% versus industry average of -3.4%
Return on Assets: 4.7% versus industry average of 0.5%
Return on Capital: 7.8% versus industry average of 0.8%
Receivable Turnover: 19.9 versus industry average of 27.4



Wednesday, August 12th, 2009 Uncategorized Comments Off on Five Star Quality Care, Inc. (FVE)
Top Small Cap Market News